Newsletter

Menu

GW Pharma Q4 results fails to impress the street

By Staff Correspondent |

GW Pharmaceuticals plc (Nasdaq: GWPH) stock was down about 4% in the extended hours of trading after the company missed analyst estimates for the fourth quarter.

Sales for the biopharma firm came in at $2.42 million, which dipped modestly by 1% over last year. The dip in revenues was due to flat product sales compared to the prior year period. Fourth quarter revenues failed to beat street consensus.

The company’s loss increased 28% to $0.23 per share compared to $0.18 loss per share reported in the prior year period. The double-digit jump in the loss was due to increased selling, general and administrative (SG&A) expenses. GW reported $52.7 million as SG&A expenses in the fourth quarter, which has more than doubled from $19.4 million reported last year.

On November 26, GW’s frontline cannabinoid drug Epidiolex reported positive results in the second Phase 3 trial for treating patients diagnosed with the Dravet syndrome, a rare form of epilepsy which causes seizures right from the childhood. On November 1st, the drug was available in the US by physician prescription. It is estimated that there are 2.2 million people in the US who suffer from epilepsy and nearly 470,000 are children.

The ‘midterm’ shot sends cannabis stocks to a new high

It’s worth noting that Epidiolex was approved by the US FDA in June 2018 to treat patients who are suffering from seizures relating to Dravet syndrome or Lennox-Gastaut syndrome (LGS). The company filed a marketing authorization application with European Medicines Agency (EMA) and expects to receive approval from the regulator by the first quarter of 2019.

Epidiolex competes with Fintepla from Zogenix (ZGNX). Fintepla is a low-dose fenfluramine formulation drug to treat patients with the Dravet syndrome. Zogenix has kickstarted the rolling submission of new drug application filing to FDA for treating patients with the Dravet syndrome. The low-dose fenfluramine drug has also shown positive results in LGS with Zogenix is currently enrolling patients for phase 3 clinical trial of Fintepla for patients diagnosed with LGS.

GW’s share is marginally down about 3% in 2018, while the biopharma stock has lost more than 7% in the last 12 months.

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Advertisement

More on this Company

MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales

July 29, 2025
ipo news

Guardian Pharmacy seeks to raise up to $108 mil in US IPO

September 17, 2024
ipo news

Everything you need to know about Zenas BioPharma’s IPO

August 27, 2024

205 responses to “GW Pharma Q4 results fails to impress the street”

  20. educational quality

    […]Wonderful story, reckoned we could combine a couple of unrelated information, nevertheless definitely really worth taking a appear, whoa did a single master about Mid East has got more problerms at the same time […]

  22. MBA

    […]Wonderful story, reckoned we could combine a number of unrelated data, nonetheless definitely worth taking a look, whoa did one particular discover about Mid East has got a lot more problerms as well […]

  54. miniature french bulldog

    […]Wonderful story, reckoned we could combine a handful of unrelated information, nonetheless actually really worth taking a appear, whoa did one particular find out about Mid East has got more problerms at the same time […]

  84. Classic Books 500

    […]Wonderful story, reckoned we could combine a number of unrelated information, nonetheless genuinely really worth taking a search, whoa did one particular understand about Mid East has got a lot more problerms as well […]

  137. Hair care

    […]we like to honor several other world wide web web sites on the net, even when they aren’t linked to us, by linking to them. Beneath are some webpages really worth checking out[…]

  178. 늑대닷컴

    […]we prefer to honor many other internet web-sites on the net, even when they aren’t linked to us, by linking to them. Underneath are some webpages really worth checking out[…]

  180. 늑대닷컴

    […]Wonderful story, reckoned we could combine a couple of unrelated information, nonetheless actually worth taking a look, whoa did one study about Mid East has got much more problerms too […]

  182. dr kim acupuncture

    […]Wonderful story, reckoned we could combine some unrelated information, nonetheless truly really worth taking a look, whoa did one particular master about Mid East has got additional problerms at the same time […]

Leave a Reply

Top